Bosutinib Induces High Response Rates in Imatinib-Resistant, -Intolerant Patients

2010 Jun 21, N Osterweil

CHICAGO (EGMN) - Bosutinib shows clinical efficacy in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase, with complete cytogenetic response rates of 50% in a multinational study, investigators reported.

At 24 months of follow-up, 77% of imatinib (Gleevec)-resistant patients and 86% of imatinib-intolerant patients who were treated with the investigational drug were alive without evidence of disease progression, and median progression-free survival has not yet been reached in either group, according to Dr. Jorge E. Cortes of the University of Texas M.D. Anderson Cancer Center in Houston.....more

www.oncologystat.com/news/Bosutinib_Induces_High_Response_Rates_in_Imati...